Cost Analysis of High-Flow Oxygen Therapy Compared with Conventional Oxygen Therapy in Severe COVID-19 in Colombia: Data from a Randomized Clinical Trial

Sergio I Prada,1,2 Maria P Garcia-Garcia,1 Gustavo A Ospina-Tascón,3,4 Diego Rosselli5 1Fundación Valle del Lili, Centro de Investigaciones Clínicas, Cali, Colombia; 2Universidad Icesi, Centro PROESA, Cali, Colombia; 3Department of Intensive Care, Fundación Valle del Lili, Cali, Colombia; 4Translational Medicine Laboratory in Critical Care (TransLab-CCM), Universidad Icesi, Cali, Colombia; 5Clinical Epidemiology and Biostatistics Department, Pontificia Universidad Javeriana, Bogota, ColombiaCorrespondence: Sergio I Prada, Centro de Investigaciones Clínicas, Fundación Valle del Lili, Cra. 98 18-49, Cali, Valle, Colombia, Email sergio.pradafvl.org.coBackground: A randomized clinical trial (HiFlo-COVID-19 Trial) showed that among patients with severe COVID-19, treatment with high-flow oxygen therapy (HFOT) significantly reduced the need for invasive mechanical ventilation support and time for clinical recovery compared with conventional oxygen therapy (COT). However, the cost of this strategy is unknown.Objective: We examined total cost of HFOT treatment compared with COT in real-world setting.Methods: We conducted a post-trial-based cost analysis from the perspective of a managed competition healthcare system, using actual records of billed costs. Cost categories include general ward, intensive care unit, procedures, imaging, laboratories, medications, supplies, and others.Results: A total of 188 participants (mean age 60, 33% female) were included. Average costs (and standard deviation) in the HFOT group were USD &dollar;7992 (7394) and in the COT group USD &dollar; 10,190 (9402). Differences, however, did not reach statistical significance (P=0.093). However, resource use was always less costly for the HNFO group, with an overall percentage decrease of 27%. Two categories make up 72% of all savings: medications (41%) and intensive care unit (31%).Conclusion: For patients in ICU with severe COVID-19 the cost of treatment with HFOT as compared to COT is likely to be cost-saving due to less use of medications and length of stay in ICU.Keywords: SARS-CoV-2, COVID-19, cost analysis, economic evaluation, high-flow nasal oxygen, conventional oxygen therapy, high-flow oxygen therapy, clinical trial, cost, Colombia Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Prada SI [verfasserIn] Garcia-Garcia MP [verfasserIn] Ospina-Tascón GA [verfasserIn] Rosselli D [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2023

Schlagwörter:	sars-cov-2 covid-19 cost analysis economic evaluation high-flow nasal oxygen conventional oxygen therapy high-flow oxygen therapy clinical trial cost colombia.

Übergeordnetes Werk:	In: ClinicoEconomics and Outcomes Research - Dove Medical Press, 2010, (2023), Seite 733-738
Übergeordnetes Werk:	year:2023 ; pages:733-738

Links:	Link aufrufen Link aufrufen Journal toc

Katalog-ID:	DOAJ090935896

Internformat


LEADER	01000naa a22002652 4500
001	DOAJ090935896
003	DE-627
005	20240412230047.0
007	cr uuu---uuuuu
008	240412s2023 xx \|\|\|\|\|o 00\| \|\|eng c
035			\|a (DE-627)DOAJ090935896
035			\|a (DE-599)DOAJa330515d5ae144e48d2ceef745caae84
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a R5-920
050		0	\|a RM1-950
100	0		\|a Prada SI \|e verfasserin \|4 aut
245	1	0	\|a Cost Analysis of High-Flow Oxygen Therapy Compared with Conventional Oxygen Therapy in Severe COVID-19 in Colombia: Data from a Randomized Clinical Trial
264		1	\|c 2023
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Sergio I Prada,1,2 Maria P Garcia-Garcia,1 Gustavo A Ospina-Tascón,3,4 Diego Rosselli5 1Fundación Valle del Lili, Centro de Investigaciones Clínicas, Cali, Colombia; 2Universidad Icesi, Centro PROESA, Cali, Colombia; 3Department of Intensive Care, Fundación Valle del Lili, Cali, Colombia; 4Translational Medicine Laboratory in Critical Care (TransLab-CCM), Universidad Icesi, Cali, Colombia; 5Clinical Epidemiology and Biostatistics Department, Pontificia Universidad Javeriana, Bogota, ColombiaCorrespondence: Sergio I Prada, Centro de Investigaciones Clínicas, Fundación Valle del Lili, Cra. 98 18-49, Cali, Valle, Colombia, Email sergio.pradafvl.org.coBackground: A randomized clinical trial (HiFlo-COVID-19 Trial) showed that among patients with severe COVID-19, treatment with high-flow oxygen therapy (HFOT) significantly reduced the need for invasive mechanical ventilation support and time for clinical recovery compared with conventional oxygen therapy (COT). However, the cost of this strategy is unknown.Objective: We examined total cost of HFOT treatment compared with COT in real-world setting.Methods: We conducted a post-trial-based cost analysis from the perspective of a managed competition healthcare system, using actual records of billed costs. Cost categories include general ward, intensive care unit, procedures, imaging, laboratories, medications, supplies, and others.Results: A total of 188 participants (mean age 60, 33% female) were included. Average costs (and standard deviation) in the HFOT group were USD &dollar;7992 (7394) and in the COT group USD &dollar; 10,190 (9402). Differences, however, did not reach statistical significance (P=0.093). However, resource use was always less costly for the HNFO group, with an overall percentage decrease of 27%. Two categories make up 72% of all savings: medications (41%) and intensive care unit (31%).Conclusion: For patients in ICU with severe COVID-19 the cost of treatment with HFOT as compared to COT is likely to be cost-saving due to less use of medications and length of stay in ICU.Keywords: SARS-CoV-2, COVID-19, cost analysis, economic evaluation, high-flow nasal oxygen, conventional oxygen therapy, high-flow oxygen therapy, clinical trial, cost, Colombia
650		4	\|a sars-cov-2
650		4	\|a covid-19
650		4	\|a cost analysis
650		4	\|a economic evaluation
650		4	\|a high-flow nasal oxygen
650		4	\|a conventional oxygen therapy
650		4	\|a high-flow oxygen therapy
650		4	\|a clinical trial
650		4	\|a cost
650		4	\|a colombia.
653		0	\|a Medicine (General)
653		0	\|a Therapeutics. Pharmacology
700	0		\|a Garcia-Garcia MP \|e verfasserin \|4 aut
700	0		\|a Ospina-Tascón GA \|e verfasserin \|4 aut
700	0		\|a Rosselli D \|e verfasserin \|4 aut
773	0	8	\|i In \|t ClinicoEconomics and Outcomes Research \|d Dove Medical Press, 2010 \|g (2023), Seite 733-738 \|w (DE-627)611725843 \|w (DE-600)2520698-9 \|x 11786981 \|7 nnns
773	1	8	\|g year:2023 \|g pages:733-738
856	4	0	\|u https://doaj.org/article/a330515d5ae144e48d2ceef745caae84 \|z kostenfrei
856	4	0	\|u https://www.dovepress.com/cost-analysis-of-high-flow-oxygen-therapy-compared-with-conventional-o-peer-reviewed-fulltext-article-CEOR \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1178-6981 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4326
912			\|a GBV_ILN_4335
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|j 2023 \|h 733-738

Indexfelder

author_variant	p s ps g g m ggm o t g otg r d rd
matchkey_str	article:11786981:2023----::otnlssfihlwxgnhrpcmaewtcnetoaoyeteayneeeoi1iclmi
hierarchy_sort_str	2023
callnumber-subject-code	R
publishDate	2023
allfields	(DE-627)DOAJ090935896 (DE-599)DOAJa330515d5ae144e48d2ceef745caae84 DE-627 ger DE-627 rakwb eng R5-920 RM1-950 Prada SI verfasserin aut Cost Analysis of High-Flow Oxygen Therapy Compared with Conventional Oxygen Therapy in Severe COVID-19 in Colombia: Data from a Randomized Clinical Trial 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Sergio I Prada,1,2 Maria P Garcia-Garcia,1 Gustavo A Ospina-Tascón,3,4 Diego Rosselli5 1Fundación Valle del Lili, Centro de Investigaciones Clínicas, Cali, Colombia; 2Universidad Icesi, Centro PROESA, Cali, Colombia; 3Department of Intensive Care, Fundación Valle del Lili, Cali, Colombia; 4Translational Medicine Laboratory in Critical Care (TransLab-CCM), Universidad Icesi, Cali, Colombia; 5Clinical Epidemiology and Biostatistics Department, Pontificia Universidad Javeriana, Bogota, ColombiaCorrespondence: Sergio I Prada, Centro de Investigaciones Clínicas, Fundación Valle del Lili, Cra. 98 18-49, Cali, Valle, Colombia, Email sergio.pradafvl.org.coBackground: A randomized clinical trial (HiFlo-COVID-19 Trial) showed that among patients with severe COVID-19, treatment with high-flow oxygen therapy (HFOT) significantly reduced the need for invasive mechanical ventilation support and time for clinical recovery compared with conventional oxygen therapy (COT). However, the cost of this strategy is unknown.Objective: We examined total cost of HFOT treatment compared with COT in real-world setting.Methods: We conducted a post-trial-based cost analysis from the perspective of a managed competition healthcare system, using actual records of billed costs. Cost categories include general ward, intensive care unit, procedures, imaging, laboratories, medications, supplies, and others.Results: A total of 188 participants (mean age 60, 33% female) were included. Average costs (and standard deviation) in the HFOT group were USD &dollar;7992 (7394) and in the COT group USD &dollar; 10,190 (9402). Differences, however, did not reach statistical significance (P=0.093). However, resource use was always less costly for the HNFO group, with an overall percentage decrease of 27%. Two categories make up 72% of all savings: medications (41%) and intensive care unit (31%).Conclusion: For patients in ICU with severe COVID-19 the cost of treatment with HFOT as compared to COT is likely to be cost-saving due to less use of medications and length of stay in ICU.Keywords: SARS-CoV-2, COVID-19, cost analysis, economic evaluation, high-flow nasal oxygen, conventional oxygen therapy, high-flow oxygen therapy, clinical trial, cost, Colombia sars-cov-2 covid-19 cost analysis economic evaluation high-flow nasal oxygen conventional oxygen therapy high-flow oxygen therapy clinical trial cost colombia. Medicine (General) Therapeutics. Pharmacology Garcia-Garcia MP verfasserin aut Ospina-Tascón GA verfasserin aut Rosselli D verfasserin aut In ClinicoEconomics and Outcomes Research Dove Medical Press, 2010 (2023), Seite 733-738 (DE-627)611725843 (DE-600)2520698-9 11786981 nnns year:2023 pages:733-738 https://doaj.org/article/a330515d5ae144e48d2ceef745caae84 kostenfrei https://www.dovepress.com/cost-analysis-of-high-flow-oxygen-therapy-compared-with-conventional-o-peer-reviewed-fulltext-article-CEOR kostenfrei https://doaj.org/toc/1178-6981 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2023 733-738
spelling	(DE-627)DOAJ090935896 (DE-599)DOAJa330515d5ae144e48d2ceef745caae84 DE-627 ger DE-627 rakwb eng R5-920 RM1-950 Prada SI verfasserin aut Cost Analysis of High-Flow Oxygen Therapy Compared with Conventional Oxygen Therapy in Severe COVID-19 in Colombia: Data from a Randomized Clinical Trial 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Sergio I Prada,1,2 Maria P Garcia-Garcia,1 Gustavo A Ospina-Tascón,3,4 Diego Rosselli5 1Fundación Valle del Lili, Centro de Investigaciones Clínicas, Cali, Colombia; 2Universidad Icesi, Centro PROESA, Cali, Colombia; 3Department of Intensive Care, Fundación Valle del Lili, Cali, Colombia; 4Translational Medicine Laboratory in Critical Care (TransLab-CCM), Universidad Icesi, Cali, Colombia; 5Clinical Epidemiology and Biostatistics Department, Pontificia Universidad Javeriana, Bogota, ColombiaCorrespondence: Sergio I Prada, Centro de Investigaciones Clínicas, Fundación Valle del Lili, Cra. 98 18-49, Cali, Valle, Colombia, Email sergio.pradafvl.org.coBackground: A randomized clinical trial (HiFlo-COVID-19 Trial) showed that among patients with severe COVID-19, treatment with high-flow oxygen therapy (HFOT) significantly reduced the need for invasive mechanical ventilation support and time for clinical recovery compared with conventional oxygen therapy (COT). However, the cost of this strategy is unknown.Objective: We examined total cost of HFOT treatment compared with COT in real-world setting.Methods: We conducted a post-trial-based cost analysis from the perspective of a managed competition healthcare system, using actual records of billed costs. Cost categories include general ward, intensive care unit, procedures, imaging, laboratories, medications, supplies, and others.Results: A total of 188 participants (mean age 60, 33% female) were included. Average costs (and standard deviation) in the HFOT group were USD &dollar;7992 (7394) and in the COT group USD &dollar; 10,190 (9402). Differences, however, did not reach statistical significance (P=0.093). However, resource use was always less costly for the HNFO group, with an overall percentage decrease of 27%. Two categories make up 72% of all savings: medications (41%) and intensive care unit (31%).Conclusion: For patients in ICU with severe COVID-19 the cost of treatment with HFOT as compared to COT is likely to be cost-saving due to less use of medications and length of stay in ICU.Keywords: SARS-CoV-2, COVID-19, cost analysis, economic evaluation, high-flow nasal oxygen, conventional oxygen therapy, high-flow oxygen therapy, clinical trial, cost, Colombia sars-cov-2 covid-19 cost analysis economic evaluation high-flow nasal oxygen conventional oxygen therapy high-flow oxygen therapy clinical trial cost colombia. Medicine (General) Therapeutics. Pharmacology Garcia-Garcia MP verfasserin aut Ospina-Tascón GA verfasserin aut Rosselli D verfasserin aut In ClinicoEconomics and Outcomes Research Dove Medical Press, 2010 (2023), Seite 733-738 (DE-627)611725843 (DE-600)2520698-9 11786981 nnns year:2023 pages:733-738 https://doaj.org/article/a330515d5ae144e48d2ceef745caae84 kostenfrei https://www.dovepress.com/cost-analysis-of-high-flow-oxygen-therapy-compared-with-conventional-o-peer-reviewed-fulltext-article-CEOR kostenfrei https://doaj.org/toc/1178-6981 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2023 733-738
allfields_unstemmed	(DE-627)DOAJ090935896 (DE-599)DOAJa330515d5ae144e48d2ceef745caae84 DE-627 ger DE-627 rakwb eng R5-920 RM1-950 Prada SI verfasserin aut Cost Analysis of High-Flow Oxygen Therapy Compared with Conventional Oxygen Therapy in Severe COVID-19 in Colombia: Data from a Randomized Clinical Trial 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Sergio I Prada,1,2 Maria P Garcia-Garcia,1 Gustavo A Ospina-Tascón,3,4 Diego Rosselli5 1Fundación Valle del Lili, Centro de Investigaciones Clínicas, Cali, Colombia; 2Universidad Icesi, Centro PROESA, Cali, Colombia; 3Department of Intensive Care, Fundación Valle del Lili, Cali, Colombia; 4Translational Medicine Laboratory in Critical Care (TransLab-CCM), Universidad Icesi, Cali, Colombia; 5Clinical Epidemiology and Biostatistics Department, Pontificia Universidad Javeriana, Bogota, ColombiaCorrespondence: Sergio I Prada, Centro de Investigaciones Clínicas, Fundación Valle del Lili, Cra. 98 18-49, Cali, Valle, Colombia, Email sergio.pradafvl.org.coBackground: A randomized clinical trial (HiFlo-COVID-19 Trial) showed that among patients with severe COVID-19, treatment with high-flow oxygen therapy (HFOT) significantly reduced the need for invasive mechanical ventilation support and time for clinical recovery compared with conventional oxygen therapy (COT). However, the cost of this strategy is unknown.Objective: We examined total cost of HFOT treatment compared with COT in real-world setting.Methods: We conducted a post-trial-based cost analysis from the perspective of a managed competition healthcare system, using actual records of billed costs. Cost categories include general ward, intensive care unit, procedures, imaging, laboratories, medications, supplies, and others.Results: A total of 188 participants (mean age 60, 33% female) were included. Average costs (and standard deviation) in the HFOT group were USD &dollar;7992 (7394) and in the COT group USD &dollar; 10,190 (9402). Differences, however, did not reach statistical significance (P=0.093). However, resource use was always less costly for the HNFO group, with an overall percentage decrease of 27%. Two categories make up 72% of all savings: medications (41%) and intensive care unit (31%).Conclusion: For patients in ICU with severe COVID-19 the cost of treatment with HFOT as compared to COT is likely to be cost-saving due to less use of medications and length of stay in ICU.Keywords: SARS-CoV-2, COVID-19, cost analysis, economic evaluation, high-flow nasal oxygen, conventional oxygen therapy, high-flow oxygen therapy, clinical trial, cost, Colombia sars-cov-2 covid-19 cost analysis economic evaluation high-flow nasal oxygen conventional oxygen therapy high-flow oxygen therapy clinical trial cost colombia. Medicine (General) Therapeutics. Pharmacology Garcia-Garcia MP verfasserin aut Ospina-Tascón GA verfasserin aut Rosselli D verfasserin aut In ClinicoEconomics and Outcomes Research Dove Medical Press, 2010 (2023), Seite 733-738 (DE-627)611725843 (DE-600)2520698-9 11786981 nnns year:2023 pages:733-738 https://doaj.org/article/a330515d5ae144e48d2ceef745caae84 kostenfrei https://www.dovepress.com/cost-analysis-of-high-flow-oxygen-therapy-compared-with-conventional-o-peer-reviewed-fulltext-article-CEOR kostenfrei https://doaj.org/toc/1178-6981 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2023 733-738
allfieldsGer	(DE-627)DOAJ090935896 (DE-599)DOAJa330515d5ae144e48d2ceef745caae84 DE-627 ger DE-627 rakwb eng R5-920 RM1-950 Prada SI verfasserin aut Cost Analysis of High-Flow Oxygen Therapy Compared with Conventional Oxygen Therapy in Severe COVID-19 in Colombia: Data from a Randomized Clinical Trial 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Sergio I Prada,1,2 Maria P Garcia-Garcia,1 Gustavo A Ospina-Tascón,3,4 Diego Rosselli5 1Fundación Valle del Lili, Centro de Investigaciones Clínicas, Cali, Colombia; 2Universidad Icesi, Centro PROESA, Cali, Colombia; 3Department of Intensive Care, Fundación Valle del Lili, Cali, Colombia; 4Translational Medicine Laboratory in Critical Care (TransLab-CCM), Universidad Icesi, Cali, Colombia; 5Clinical Epidemiology and Biostatistics Department, Pontificia Universidad Javeriana, Bogota, ColombiaCorrespondence: Sergio I Prada, Centro de Investigaciones Clínicas, Fundación Valle del Lili, Cra. 98 18-49, Cali, Valle, Colombia, Email sergio.pradafvl.org.coBackground: A randomized clinical trial (HiFlo-COVID-19 Trial) showed that among patients with severe COVID-19, treatment with high-flow oxygen therapy (HFOT) significantly reduced the need for invasive mechanical ventilation support and time for clinical recovery compared with conventional oxygen therapy (COT). However, the cost of this strategy is unknown.Objective: We examined total cost of HFOT treatment compared with COT in real-world setting.Methods: We conducted a post-trial-based cost analysis from the perspective of a managed competition healthcare system, using actual records of billed costs. Cost categories include general ward, intensive care unit, procedures, imaging, laboratories, medications, supplies, and others.Results: A total of 188 participants (mean age 60, 33% female) were included. Average costs (and standard deviation) in the HFOT group were USD &dollar;7992 (7394) and in the COT group USD &dollar; 10,190 (9402). Differences, however, did not reach statistical significance (P=0.093). However, resource use was always less costly for the HNFO group, with an overall percentage decrease of 27%. Two categories make up 72% of all savings: medications (41%) and intensive care unit (31%).Conclusion: For patients in ICU with severe COVID-19 the cost of treatment with HFOT as compared to COT is likely to be cost-saving due to less use of medications and length of stay in ICU.Keywords: SARS-CoV-2, COVID-19, cost analysis, economic evaluation, high-flow nasal oxygen, conventional oxygen therapy, high-flow oxygen therapy, clinical trial, cost, Colombia sars-cov-2 covid-19 cost analysis economic evaluation high-flow nasal oxygen conventional oxygen therapy high-flow oxygen therapy clinical trial cost colombia. Medicine (General) Therapeutics. Pharmacology Garcia-Garcia MP verfasserin aut Ospina-Tascón GA verfasserin aut Rosselli D verfasserin aut In ClinicoEconomics and Outcomes Research Dove Medical Press, 2010 (2023), Seite 733-738 (DE-627)611725843 (DE-600)2520698-9 11786981 nnns year:2023 pages:733-738 https://doaj.org/article/a330515d5ae144e48d2ceef745caae84 kostenfrei https://www.dovepress.com/cost-analysis-of-high-flow-oxygen-therapy-compared-with-conventional-o-peer-reviewed-fulltext-article-CEOR kostenfrei https://doaj.org/toc/1178-6981 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2023 733-738
allfieldsSound	(DE-627)DOAJ090935896 (DE-599)DOAJa330515d5ae144e48d2ceef745caae84 DE-627 ger DE-627 rakwb eng R5-920 RM1-950 Prada SI verfasserin aut Cost Analysis of High-Flow Oxygen Therapy Compared with Conventional Oxygen Therapy in Severe COVID-19 in Colombia: Data from a Randomized Clinical Trial 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Sergio I Prada,1,2 Maria P Garcia-Garcia,1 Gustavo A Ospina-Tascón,3,4 Diego Rosselli5 1Fundación Valle del Lili, Centro de Investigaciones Clínicas, Cali, Colombia; 2Universidad Icesi, Centro PROESA, Cali, Colombia; 3Department of Intensive Care, Fundación Valle del Lili, Cali, Colombia; 4Translational Medicine Laboratory in Critical Care (TransLab-CCM), Universidad Icesi, Cali, Colombia; 5Clinical Epidemiology and Biostatistics Department, Pontificia Universidad Javeriana, Bogota, ColombiaCorrespondence: Sergio I Prada, Centro de Investigaciones Clínicas, Fundación Valle del Lili, Cra. 98 18-49, Cali, Valle, Colombia, Email sergio.pradafvl.org.coBackground: A randomized clinical trial (HiFlo-COVID-19 Trial) showed that among patients with severe COVID-19, treatment with high-flow oxygen therapy (HFOT) significantly reduced the need for invasive mechanical ventilation support and time for clinical recovery compared with conventional oxygen therapy (COT). However, the cost of this strategy is unknown.Objective: We examined total cost of HFOT treatment compared with COT in real-world setting.Methods: We conducted a post-trial-based cost analysis from the perspective of a managed competition healthcare system, using actual records of billed costs. Cost categories include general ward, intensive care unit, procedures, imaging, laboratories, medications, supplies, and others.Results: A total of 188 participants (mean age 60, 33% female) were included. Average costs (and standard deviation) in the HFOT group were USD &dollar;7992 (7394) and in the COT group USD &dollar; 10,190 (9402). Differences, however, did not reach statistical significance (P=0.093). However, resource use was always less costly for the HNFO group, with an overall percentage decrease of 27%. Two categories make up 72% of all savings: medications (41%) and intensive care unit (31%).Conclusion: For patients in ICU with severe COVID-19 the cost of treatment with HFOT as compared to COT is likely to be cost-saving due to less use of medications and length of stay in ICU.Keywords: SARS-CoV-2, COVID-19, cost analysis, economic evaluation, high-flow nasal oxygen, conventional oxygen therapy, high-flow oxygen therapy, clinical trial, cost, Colombia sars-cov-2 covid-19 cost analysis economic evaluation high-flow nasal oxygen conventional oxygen therapy high-flow oxygen therapy clinical trial cost colombia. Medicine (General) Therapeutics. Pharmacology Garcia-Garcia MP verfasserin aut Ospina-Tascón GA verfasserin aut Rosselli D verfasserin aut In ClinicoEconomics and Outcomes Research Dove Medical Press, 2010 (2023), Seite 733-738 (DE-627)611725843 (DE-600)2520698-9 11786981 nnns year:2023 pages:733-738 https://doaj.org/article/a330515d5ae144e48d2ceef745caae84 kostenfrei https://www.dovepress.com/cost-analysis-of-high-flow-oxygen-therapy-compared-with-conventional-o-peer-reviewed-fulltext-article-CEOR kostenfrei https://doaj.org/toc/1178-6981 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2023 733-738
language	English
source	In ClinicoEconomics and Outcomes Research (2023), Seite 733-738 year:2023 pages:733-738
sourceStr	In ClinicoEconomics and Outcomes Research (2023), Seite 733-738 year:2023 pages:733-738
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	sars-cov-2 covid-19 cost analysis economic evaluation high-flow nasal oxygen conventional oxygen therapy high-flow oxygen therapy clinical trial cost colombia. Medicine (General) Therapeutics. Pharmacology
isfreeaccess_bool	true
container_title	ClinicoEconomics and Outcomes Research
authorswithroles_txt_mv	Prada SI @@aut@@ Garcia-Garcia MP @@aut@@ Ospina-Tascón GA @@aut@@ Rosselli D @@aut@@
publishDateDaySort_date	2023-01-01T00:00:00Z
hierarchy_top_id	611725843
id	DOAJ090935896
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ090935896</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240412230047.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240412s2023 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ090935896</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJa330515d5ae144e48d2ceef745caae84</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R5-920</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Prada SI</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Cost Analysis of High-Flow Oxygen Therapy Compared with Conventional Oxygen Therapy in Severe COVID-19 in Colombia: Data from a Randomized Clinical Trial</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Sergio I Prada,1,2 Maria P Garcia-Garcia,1 Gustavo A Ospina-Tascón,3,4 Diego Rosselli5 1Fundación Valle del Lili, Centro de Investigaciones Clínicas, Cali, Colombia; 2Universidad Icesi, Centro PROESA, Cali, Colombia; 3Department of Intensive Care, Fundación Valle del Lili, Cali, Colombia; 4Translational Medicine Laboratory in Critical Care (TransLab-CCM), Universidad Icesi, Cali, Colombia; 5Clinical Epidemiology and Biostatistics Department, Pontificia Universidad Javeriana, Bogota, ColombiaCorrespondence: Sergio I Prada, Centro de Investigaciones Clínicas, Fundación Valle del Lili, Cra. 98 18-49, Cali, Valle, Colombia, Email sergio.pradafvl.org.coBackground: A randomized clinical trial (HiFlo-COVID-19 Trial) showed that among patients with severe COVID-19, treatment with high-flow oxygen therapy (HFOT) significantly reduced the need for invasive mechanical ventilation support and time for clinical recovery compared with conventional oxygen therapy (COT). However, the cost of this strategy is unknown.Objective: We examined total cost of HFOT treatment compared with COT in real-world setting.Methods: We conducted a post-trial-based cost analysis from the perspective of a managed competition healthcare system, using actual records of billed costs. Cost categories include general ward, intensive care unit, procedures, imaging, laboratories, medications, supplies, and others.Results: A total of 188 participants (mean age 60, 33% female) were included. Average costs (and standard deviation) in the HFOT group were USD &dollar;7992 (7394) and in the COT group USD &dollar; 10,190 (9402). Differences, however, did not reach statistical significance (P=0.093). However, resource use was always less costly for the HNFO group, with an overall percentage decrease of 27%. Two categories make up 72% of all savings: medications (41%) and intensive care unit (31%).Conclusion: For patients in ICU with severe COVID-19 the cost of treatment with HFOT as compared to COT is likely to be cost-saving due to less use of medications and length of stay in ICU.Keywords: SARS-CoV-2, COVID-19, cost analysis, economic evaluation, high-flow nasal oxygen, conventional oxygen therapy, high-flow oxygen therapy, clinical trial, cost, Colombia</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">sars-cov-2</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">covid-19</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cost analysis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">economic evaluation</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">high-flow nasal oxygen</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">conventional oxygen therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">high-flow oxygen therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">clinical trial</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cost</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">colombia.</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine (General)</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Garcia-Garcia MP</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ospina-Tascón GA</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rosselli D</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">ClinicoEconomics and Outcomes Research</subfield><subfield code="d">Dove Medical Press, 2010</subfield><subfield code="g">(2023), Seite 733-738</subfield><subfield code="w">(DE-627)611725843</subfield><subfield code="w">(DE-600)2520698-9</subfield><subfield code="x">11786981</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2023</subfield><subfield code="g">pages:733-738</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/a330515d5ae144e48d2ceef745caae84</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.dovepress.com/cost-analysis-of-high-flow-oxygen-therapy-compared-with-conventional-o-peer-reviewed-fulltext-article-CEOR</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1178-6981</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2023</subfield><subfield code="h">733-738</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Prada SI
spellingShingle	Prada SI misc R5-920 misc RM1-950 misc sars-cov-2 misc covid-19 misc cost analysis misc economic evaluation misc high-flow nasal oxygen misc conventional oxygen therapy misc high-flow oxygen therapy misc clinical trial misc cost misc colombia. misc Medicine (General) misc Therapeutics. Pharmacology Cost Analysis of High-Flow Oxygen Therapy Compared with Conventional Oxygen Therapy in Severe COVID-19 in Colombia: Data from a Randomized Clinical Trial
authorStr	Prada SI
ppnlink_with_tag_str_mv	@@773@@(DE-627)611725843
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	R5-920
illustrated	Not Illustrated
issn	11786981
topic_title	R5-920 RM1-950 Cost Analysis of High-Flow Oxygen Therapy Compared with Conventional Oxygen Therapy in Severe COVID-19 in Colombia: Data from a Randomized Clinical Trial sars-cov-2 covid-19 cost analysis economic evaluation high-flow nasal oxygen conventional oxygen therapy high-flow oxygen therapy clinical trial cost colombia
topic	misc R5-920 misc RM1-950 misc sars-cov-2 misc covid-19 misc cost analysis misc economic evaluation misc high-flow nasal oxygen misc conventional oxygen therapy misc high-flow oxygen therapy misc clinical trial misc cost misc colombia. misc Medicine (General) misc Therapeutics. Pharmacology
topic_unstemmed	misc R5-920 misc RM1-950 misc sars-cov-2 misc covid-19 misc cost analysis misc economic evaluation misc high-flow nasal oxygen misc conventional oxygen therapy misc high-flow oxygen therapy misc clinical trial misc cost misc colombia. misc Medicine (General) misc Therapeutics. Pharmacology
topic_browse	misc R5-920 misc RM1-950 misc sars-cov-2 misc covid-19 misc cost analysis misc economic evaluation misc high-flow nasal oxygen misc conventional oxygen therapy misc high-flow oxygen therapy misc clinical trial misc cost misc colombia. misc Medicine (General) misc Therapeutics. Pharmacology
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	ClinicoEconomics and Outcomes Research
hierarchy_parent_id	611725843
hierarchy_top_title	ClinicoEconomics and Outcomes Research
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)611725843 (DE-600)2520698-9
title	Cost Analysis of High-Flow Oxygen Therapy Compared with Conventional Oxygen Therapy in Severe COVID-19 in Colombia: Data from a Randomized Clinical Trial
ctrlnum	(DE-627)DOAJ090935896 (DE-599)DOAJa330515d5ae144e48d2ceef745caae84
title_full	Cost Analysis of High-Flow Oxygen Therapy Compared with Conventional Oxygen Therapy in Severe COVID-19 in Colombia: Data from a Randomized Clinical Trial
author_sort	Prada SI
journal	ClinicoEconomics and Outcomes Research
journalStr	ClinicoEconomics and Outcomes Research
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2023
contenttype_str_mv	txt
container_start_page	733
author_browse	Prada SI Garcia-Garcia MP Ospina-Tascón GA Rosselli D
class	R5-920 RM1-950
format_se	Elektronische Aufsätze
author-letter	Prada SI
author2-role	verfasserin
title_sort	cost analysis of high-flow oxygen therapy compared with conventional oxygen therapy in severe covid-19 in colombia: data from a randomized clinical trial
callnumber	R5-920
title_auth	Cost Analysis of High-Flow Oxygen Therapy Compared with Conventional Oxygen Therapy in Severe COVID-19 in Colombia: Data from a Randomized Clinical Trial
abstract	Sergio I Prada,1,2 Maria P Garcia-Garcia,1 Gustavo A Ospina-Tascón,3,4 Diego Rosselli5 1Fundación Valle del Lili, Centro de Investigaciones Clínicas, Cali, Colombia; 2Universidad Icesi, Centro PROESA, Cali, Colombia; 3Department of Intensive Care, Fundación Valle del Lili, Cali, Colombia; 4Translational Medicine Laboratory in Critical Care (TransLab-CCM), Universidad Icesi, Cali, Colombia; 5Clinical Epidemiology and Biostatistics Department, Pontificia Universidad Javeriana, Bogota, ColombiaCorrespondence: Sergio I Prada, Centro de Investigaciones Clínicas, Fundación Valle del Lili, Cra. 98 18-49, Cali, Valle, Colombia, Email sergio.pradafvl.org.coBackground: A randomized clinical trial (HiFlo-COVID-19 Trial) showed that among patients with severe COVID-19, treatment with high-flow oxygen therapy (HFOT) significantly reduced the need for invasive mechanical ventilation support and time for clinical recovery compared with conventional oxygen therapy (COT). However, the cost of this strategy is unknown.Objective: We examined total cost of HFOT treatment compared with COT in real-world setting.Methods: We conducted a post-trial-based cost analysis from the perspective of a managed competition healthcare system, using actual records of billed costs. Cost categories include general ward, intensive care unit, procedures, imaging, laboratories, medications, supplies, and others.Results: A total of 188 participants (mean age 60, 33% female) were included. Average costs (and standard deviation) in the HFOT group were USD &dollar;7992 (7394) and in the COT group USD &dollar; 10,190 (9402). Differences, however, did not reach statistical significance (P=0.093). However, resource use was always less costly for the HNFO group, with an overall percentage decrease of 27%. Two categories make up 72% of all savings: medications (41%) and intensive care unit (31%).Conclusion: For patients in ICU with severe COVID-19 the cost of treatment with HFOT as compared to COT is likely to be cost-saving due to less use of medications and length of stay in ICU.Keywords: SARS-CoV-2, COVID-19, cost analysis, economic evaluation, high-flow nasal oxygen, conventional oxygen therapy, high-flow oxygen therapy, clinical trial, cost, Colombia
abstractGer	Sergio I Prada,1,2 Maria P Garcia-Garcia,1 Gustavo A Ospina-Tascón,3,4 Diego Rosselli5 1Fundación Valle del Lili, Centro de Investigaciones Clínicas, Cali, Colombia; 2Universidad Icesi, Centro PROESA, Cali, Colombia; 3Department of Intensive Care, Fundación Valle del Lili, Cali, Colombia; 4Translational Medicine Laboratory in Critical Care (TransLab-CCM), Universidad Icesi, Cali, Colombia; 5Clinical Epidemiology and Biostatistics Department, Pontificia Universidad Javeriana, Bogota, ColombiaCorrespondence: Sergio I Prada, Centro de Investigaciones Clínicas, Fundación Valle del Lili, Cra. 98 18-49, Cali, Valle, Colombia, Email sergio.pradafvl.org.coBackground: A randomized clinical trial (HiFlo-COVID-19 Trial) showed that among patients with severe COVID-19, treatment with high-flow oxygen therapy (HFOT) significantly reduced the need for invasive mechanical ventilation support and time for clinical recovery compared with conventional oxygen therapy (COT). However, the cost of this strategy is unknown.Objective: We examined total cost of HFOT treatment compared with COT in real-world setting.Methods: We conducted a post-trial-based cost analysis from the perspective of a managed competition healthcare system, using actual records of billed costs. Cost categories include general ward, intensive care unit, procedures, imaging, laboratories, medications, supplies, and others.Results: A total of 188 participants (mean age 60, 33% female) were included. Average costs (and standard deviation) in the HFOT group were USD &dollar;7992 (7394) and in the COT group USD &dollar; 10,190 (9402). Differences, however, did not reach statistical significance (P=0.093). However, resource use was always less costly for the HNFO group, with an overall percentage decrease of 27%. Two categories make up 72% of all savings: medications (41%) and intensive care unit (31%).Conclusion: For patients in ICU with severe COVID-19 the cost of treatment with HFOT as compared to COT is likely to be cost-saving due to less use of medications and length of stay in ICU.Keywords: SARS-CoV-2, COVID-19, cost analysis, economic evaluation, high-flow nasal oxygen, conventional oxygen therapy, high-flow oxygen therapy, clinical trial, cost, Colombia
abstract_unstemmed	Sergio I Prada,1,2 Maria P Garcia-Garcia,1 Gustavo A Ospina-Tascón,3,4 Diego Rosselli5 1Fundación Valle del Lili, Centro de Investigaciones Clínicas, Cali, Colombia; 2Universidad Icesi, Centro PROESA, Cali, Colombia; 3Department of Intensive Care, Fundación Valle del Lili, Cali, Colombia; 4Translational Medicine Laboratory in Critical Care (TransLab-CCM), Universidad Icesi, Cali, Colombia; 5Clinical Epidemiology and Biostatistics Department, Pontificia Universidad Javeriana, Bogota, ColombiaCorrespondence: Sergio I Prada, Centro de Investigaciones Clínicas, Fundación Valle del Lili, Cra. 98 18-49, Cali, Valle, Colombia, Email sergio.pradafvl.org.coBackground: A randomized clinical trial (HiFlo-COVID-19 Trial) showed that among patients with severe COVID-19, treatment with high-flow oxygen therapy (HFOT) significantly reduced the need for invasive mechanical ventilation support and time for clinical recovery compared with conventional oxygen therapy (COT). However, the cost of this strategy is unknown.Objective: We examined total cost of HFOT treatment compared with COT in real-world setting.Methods: We conducted a post-trial-based cost analysis from the perspective of a managed competition healthcare system, using actual records of billed costs. Cost categories include general ward, intensive care unit, procedures, imaging, laboratories, medications, supplies, and others.Results: A total of 188 participants (mean age 60, 33% female) were included. Average costs (and standard deviation) in the HFOT group were USD &dollar;7992 (7394) and in the COT group USD &dollar; 10,190 (9402). Differences, however, did not reach statistical significance (P=0.093). However, resource use was always less costly for the HNFO group, with an overall percentage decrease of 27%. Two categories make up 72% of all savings: medications (41%) and intensive care unit (31%).Conclusion: For patients in ICU with severe COVID-19 the cost of treatment with HFOT as compared to COT is likely to be cost-saving due to less use of medications and length of stay in ICU.Keywords: SARS-CoV-2, COVID-19, cost analysis, economic evaluation, high-flow nasal oxygen, conventional oxygen therapy, high-flow oxygen therapy, clinical trial, cost, Colombia
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
title_short	Cost Analysis of High-Flow Oxygen Therapy Compared with Conventional Oxygen Therapy in Severe COVID-19 in Colombia: Data from a Randomized Clinical Trial
url	https://doaj.org/article/a330515d5ae144e48d2ceef745caae84 https://www.dovepress.com/cost-analysis-of-high-flow-oxygen-therapy-compared-with-conventional-o-peer-reviewed-fulltext-article-CEOR https://doaj.org/toc/1178-6981
remote_bool	true
author2	Garcia-Garcia MP Ospina-Tascón GA Rosselli D
author2Str	Garcia-Garcia MP Ospina-Tascón GA Rosselli D
ppnlink	611725843
callnumber-subject	R - General Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
callnumber-a	R5-920
up_date	2024-07-03T17:28:58.182Z
_version_	1803579805595074560
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ090935896</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240412230047.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240412s2023 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ090935896</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJa330515d5ae144e48d2ceef745caae84</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R5-920</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Prada SI</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Cost Analysis of High-Flow Oxygen Therapy Compared with Conventional Oxygen Therapy in Severe COVID-19 in Colombia: Data from a Randomized Clinical Trial</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Sergio I Prada,1,2 Maria P Garcia-Garcia,1 Gustavo A Ospina-Tascón,3,4 Diego Rosselli5 1Fundación Valle del Lili, Centro de Investigaciones Clínicas, Cali, Colombia; 2Universidad Icesi, Centro PROESA, Cali, Colombia; 3Department of Intensive Care, Fundación Valle del Lili, Cali, Colombia; 4Translational Medicine Laboratory in Critical Care (TransLab-CCM), Universidad Icesi, Cali, Colombia; 5Clinical Epidemiology and Biostatistics Department, Pontificia Universidad Javeriana, Bogota, ColombiaCorrespondence: Sergio I Prada, Centro de Investigaciones Clínicas, Fundación Valle del Lili, Cra. 98 18-49, Cali, Valle, Colombia, Email sergio.pradafvl.org.coBackground: A randomized clinical trial (HiFlo-COVID-19 Trial) showed that among patients with severe COVID-19, treatment with high-flow oxygen therapy (HFOT) significantly reduced the need for invasive mechanical ventilation support and time for clinical recovery compared with conventional oxygen therapy (COT). However, the cost of this strategy is unknown.Objective: We examined total cost of HFOT treatment compared with COT in real-world setting.Methods: We conducted a post-trial-based cost analysis from the perspective of a managed competition healthcare system, using actual records of billed costs. Cost categories include general ward, intensive care unit, procedures, imaging, laboratories, medications, supplies, and others.Results: A total of 188 participants (mean age 60, 33% female) were included. Average costs (and standard deviation) in the HFOT group were USD &dollar;7992 (7394) and in the COT group USD &dollar; 10,190 (9402). Differences, however, did not reach statistical significance (P=0.093). However, resource use was always less costly for the HNFO group, with an overall percentage decrease of 27%. Two categories make up 72% of all savings: medications (41%) and intensive care unit (31%).Conclusion: For patients in ICU with severe COVID-19 the cost of treatment with HFOT as compared to COT is likely to be cost-saving due to less use of medications and length of stay in ICU.Keywords: SARS-CoV-2, COVID-19, cost analysis, economic evaluation, high-flow nasal oxygen, conventional oxygen therapy, high-flow oxygen therapy, clinical trial, cost, Colombia</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">sars-cov-2</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">covid-19</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cost analysis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">economic evaluation</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">high-flow nasal oxygen</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">conventional oxygen therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">high-flow oxygen therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">clinical trial</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cost</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">colombia.</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine (General)</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Garcia-Garcia MP</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ospina-Tascón GA</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rosselli D</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">ClinicoEconomics and Outcomes Research</subfield><subfield code="d">Dove Medical Press, 2010</subfield><subfield code="g">(2023), Seite 733-738</subfield><subfield code="w">(DE-627)611725843</subfield><subfield code="w">(DE-600)2520698-9</subfield><subfield code="x">11786981</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2023</subfield><subfield code="g">pages:733-738</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/a330515d5ae144e48d2ceef745caae84</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.dovepress.com/cost-analysis-of-high-flow-oxygen-therapy-compared-with-conventional-o-peer-reviewed-fulltext-article-CEOR</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1178-6981</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2023</subfield><subfield code="h">733-738</subfield></datafield></record></collection>
score	7.401372

Nicht das Richtige dabei?

Schreiben Sie uns!

Cost Analysis of High-Flow Oxygen Therapy Compared with Conventional Oxygen Therapy in Severe COVID-19 in Colombia: Data from a Randomized Clinical Trial

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?